Inwald, E. C. and Ortmann, O. and Zeman, F. and Koller, M. and Hofstaedter, F. and Gerstenhauer, M. and Klinkhammer-Schalke, M. (2014) Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry. BIOMED RESEARCH INTERNATIONAL: 137304. ISSN 2314-6133, 2314-6141
Full text not available from this repository. (Request a copy)Abstract
Even though randomized controlled clinical trials demonstrated improved survival by adjuvant trastuzumab treatment of HER2-positive breast cancer patients, data on its effect in clinical routine are scarce. This study evaluated the use and efficacy of trastuzumab in routine treatment of HER2-positive breast cancer patients. Data from the clinical cancer registry Regensburg (Germany) were analyzed. The present study investigated 6,991 female patients with primary invasive breast cancer. In premenopausal HER2-positive patients a considerable increase of trastuzumab therapy was observed from 58.1% in 2006 to 90.9% in 2011, whereas in postmenopausal patients trastuzumab was rather used on a constant rate of 49.1%. Best overall survival (OS) was found in HER2/steroid hormone receptor-positive patients receiving guideline concordant treatment with trastuzumab plus chemotherapy (CHT) plus antihormone therapy (AHT) with a 7-year OS rate of 96% compared to the non-trastuzumab group with a 7-year OS rate of 92%. In multivariable analysis, HER2-positive patients treated with CHT or AHT who did not get trastuzumab, had a worse 7-year OS (65%, P = 0.006 versus 79%, P = 0.017) than the control groups. This population-based study demonstrated that guideline concordant use of adjuvant trastuzumab improves OS for HER2-positive breast cancer patients treated in routine clinical care.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ADHERENT ADJUVANT TREATMENT; PHASE-II TRIAL; MULTICENTER COHORT; CLINICAL-ONCOLOGY/COLLEGE; MONOCLONAL-ANTIBODY; AMERICAN-SOCIETY; FOLLOW-UP; TRASTUZUMAB; CHEMOTHERAPY; RECOMMENDATIONS; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Frauenheilkunde und Geburtshilfe (Schwerpunkt Frauenheilkunde) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 29 Nov 2019 10:57 |
| Last Modified: | 29 Nov 2019 10:57 |
| URI: | https://pred.uni-regensburg.de/id/eprint/11021 |
Actions (login required)
 |
View Item |
